Biomarkers.

Background: Cognitive impairment is a major symptom among patients with post-acute sequelae of COVID-19; the underlying pathogenesis is unknown. This impairment may be associated with changes in the level of plasma biomarkers of neurodegeneration and neuroinflammation.

Method: Plasma samples were collected from COVID-19 patients (Covpos, median 724 days from index SARS-CoV-2 infection), and from non-COVID-19 controls (Covneg; no history of SARS-CoV-2 infection and negative SARS-CoV-2 nucleocapsid antibody).

Biomarkers.

Background: Vascular Contributions to Cognitive Impairment and Dementia (VCID) is the second most common cause of dementia. Cerebral amyloid angiopathy (CAA), as one of the vascular pathologies underlying VCID, often coexists with Alzheimer's disease (AD). The New World non-human primate species, squirrel monkey (SQM), is a preclinical model of AD pathology that naturally develops extensive age-associated CAA, and therefore holds immense translational value to study biomarkers and novel therapeutic approaches for AD and CAA.

Biomarkers.

Background: A decline in gait has been associated with an escalated risk of cognitive decline and changes in Alzheimer's disease (AD) biomarkers, thus offering prognostic insight. However, the utility of gait analysis in preclinical stages of AD is unclear, and prior studies have primarily used qualitative or gross measures of gait. Furthermore, gait analysis has predominantly been performed in cohorts of non-Hispanic Whites.

Biomarkers.

Background: Subjective cognitive decline (SCD) is thought to be a preclinical stage of Alzheimer's disease (AD), associated with faster disease progression and with imaging and cerebrospinal fluid biomarkers. However, it is unclear whether and how the degree of SCD correlates with plasma biomarkers. To address this, we investigated the association of plasma biomarkers of AD with established validated measures of SCD.